Chemokine receptor modulators, production and use

• US 20040077835A1
• Filed: 01/06/2003
• Published: 04/22/2004
• Est. Priority Date: 07/12/2001
• Status: Abandoned Application

• Current Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Hartley, Oliver, Gaertner, Hubert, Offord, Robin
• Application Number:
  US10/332,038
• Publication Number:
  US 20040077835A1
• Time in Patent Office: Days
• US Class Current: 530/351
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/521 Chemokines

Abstract

Chemokine receptor modulators comprising a chemically modified carboxyl-terminus (C-terminus) and/or amino-terminus (N-terminus) for modulating potency and pharmacokinetic properties, and methods of production and use are disclosed. The compounds and methods of the invention are exemplified by novel N-terminal, C-terminal and N/C-terminal analogs of CC and CXC chemokines. The chemokine receptor modulator analogs of the invention are useful for the treatment of disorders involving the naturally occurring chemokine that the analogs of the invention antagonize, such as for the treatment of HIV and AIDS related disorders and for the treatment of asthma, allergic rhinitis, atopic dermatitis, atheroma/atherosclerosis, organ transplant rejection, and rheumatoid arthritis.

Claims

1. A chemokine receptor modulator comprising a chemokine polypeptide chain modified at its N-terminus with an aliphatic chain and one or more amino acid derivatives.

2. The chemokine receptor modulator of claim 1, wherein said chemokine polypeptide chain comprises an amino acid sequence that is substantially homologous to the amino acid sequence of a naturally occurring wild type chemokine.

3. The chemokine receptor modulator of claim 2, wherein said naturally occurring wild type chemokine is a CC chemokine.

4. The chemokine receptor modulator of claim 2, wherein said naturally occurring wild type chemokine is a CXC Chemokine.

5. The chemokine receptor modulator of claim 1, wherein said N-terminus comprises amino acids of said chemokine polypeptide chain that are N-terminal to the first disulfide-forming cysteine of said chemokine polypeptide chain.

6. The chemokine receptor modulator of claim 1, wherein said aliphatic chain is a hydrocarbon chain comprising 5 to 26 carbons.

7. The chemokine receptor modulator of claim 1, wherein said amino acid derivative has the formula —

(N-CnR-CO)—

, where n is 1-22, R is hydrogen, alkyl or aromatic, and where N and Cn, N and R, or Cn and R can form a cyclic structure.

8. A chemokine receptor modulator comprising a chemokine polypeptide chain modified at its C-terminus with an aliphatic chain or polycyclic.

9. The chemokine receptor modulator of claim 8, wherein said aliphatic chain comprises 5 to 22 carbons.

10. The chemokine receptor modulator of claim 9, wherein said aliphatic chain or polycyclic is a lipid.

12. A chemokine receptor modulator comprising a chemokine polypeptide chain modified at its N-terminus with an aliphatic chain and one or more amino acid derivatives, and at its C-terminus with an aliphatic chain or polycyclic.

13. A pharmaceutical composition comprising a chemokine receptor modulator, wherein said chemokine receptor modulator comprises a chemokine polypeptide chain modified at its N-terminus with an aliphatic chain and one or more amino acid derivatives, or a pharmaceutically acceptable salt thereof.

14. The pharmaceutical composition of claim 13, wherein said composition is in admixture with one or more pharmaceutically acceptable excipients.

15. A pharmaceutical composition comprising a chemokine receptor modulator, wherein said chemokine receptor modulator comprises a chemokine polypeptide chain modified at its C-terminus with an aliphatic chain or polycyclic, or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising the chemokine receptor modulator of claim 15 or a pharmaceutically acceptable salt thereof.

17. The pharmaceutical composition of claim 16, wherein said composition is in admixture with one or more pharmaceutically acceptable excipients.

18. A pharmaceutical composition comprising a chemokine receptor modulator comprising a chemokine polypeptide chain modified at its N-terminus with an aliphatic chain and one or more amino acid derivatives, and at its C-terminus with an aliphatic chain or polycyclic, or a pharmaceutically acceptable salt thereof.

19. The pharmaceutical composition of claim 18, wherein said composition is in admixture with one or more pharmaceutically acceptable excipients.

20. A method of treating a disease state in mammals that is alleviated by treatment with a chemokine receptor modulator, which method comprises administering to a mammal in need of such a treatment a therapeutically effective amount of a chemokine receptor modulator, wherein said chemokine receptor modulator comprises a chemokine polypeptide chain (A) modified at its N-terminus with an aliphatic chain and one or more amino acid derivatives, (B) modified at its C-terminus with an aliphatic chain or polycyclic, or (C) modified at its N-terminus with an aliphatic chain and one or more amino acid derivatives, and at its C-terminus with an aliphatic chain or polycyclic.

21. The method of claim 20, wherein the disease state is an inflammatory disease.

22. The method of claim 21, wherein the inflammatory disease is asthma, allergic rhinitis, atopic dermatitis, atheroma, atherosclerosis, or rheumatoid arthritis.

23. The method of claim 20, wherein the disease state is caused or associated with HIV infection.